中新网四川新闻5月15日电(陈默) "看到父亲能自己握着勺子吃饭，我们全家都觉得这是奇迹。"近日， 在成都京东方医院心脏中心康复出院时，曹大爷的儿子握着医护人员的手哽咽道。这位被心衰折磨8年 的七旬老人，历经5小时高难度手术、60天精心救治后重获新生的背后，是一场凝聚多学科智慧、探索 医学边界的生命保卫战。 当日的手术室里，一场精密协作悄然展开。平稳而安全的麻醉及体外循环保护下，主刀医师乔军选主任 镇静地打开患者的心脏，眼前景象让手术团队当即进入高度专注状态：巨大且懒散跳动着的心脏，主动 脉瓣膜已完全钙化，钙化物与血管壁粘连紧密，稍有不慎就会引发主动脉撕裂。主刀医师乔军选在放大 镜下实施"剥离手术"——用显微器械像剥蛋壳般分离钙化组织，每剥离1毫米都要反复确认组织边界。 "心脏停跳时间比常规手术延长30%。"麻醉科董蜀华主任紧盯着监护仪，将生命体征波动控制在极小范 围内，体外循环师周君臣则全神贯注调整血流参数，确保心肌保护液精准灌注，给手术团队创造最安全 的保障，当新瓣膜成功植入时，手术团队的手术衣已被汗水浸透，而监测屏上稳定的血流动力学数据， 宣告这场"刀尖上的舞蹈"暂告胜利。 六十日守护：三维立体的"康复 ...

Group 1: Financial Performance and Strategy - The company plans to use recent financing primarily for daily operational liquidity needs and to replace maturing debts, thereby reducing financial costs [2] - The company aims to achieve a turnaround in its net profit by focusing on its core business areas, particularly in smart city and smart healthcare sectors, in 2025 [3] - The company has been in a loss position regarding its net profit excluding non-recurring items for several years and is implementing measures to improve this situation [3] Group 2: Regulatory and Operational Updates - The company is eligible to apply for the removal of risk warnings twelve months after the issuance of an administrative penalty decision by the China Securities Regulatory Commission [3] - The recent Pingtan customs closure will not have a significant short-term impact on the company's operations, and any future impacts will be disclosed in accordance with legal requirements [3] - The investor relations activity did not involve any undisclosed significant information [3]

Group 1: Share Transfer and Control Changes - The share transfer agreement between Lu Nan and Cangnan Investment has been signed, pending regulatory approval and compliance confirmation from the Shenzhen Stock Exchange. After completion, Cangnan Finance Bureau will hold a total of 11.33% of the company's shares, becoming the actual controller [1][4] - The company is committed to timely disclosure of any necessary information as per regulatory requirements [1] Group 2: Future Development Strategy - The company focuses on "IoT-centric growth" as its core strategy for the next three years, aiming to enhance its IoT business and reduce its medical business operations [2][3] - The goal is to establish itself as a leading enterprise in the domestic RFID industry chain, with increased resource investment in IoT applications across various sectors [2] Group 3: Financial Performance - In 2024, the company's commercial intelligence business generated revenue of 500.80 million yuan, accounting for 72.50% of total revenue, while the smart medical business generated 170.31 million yuan, accounting for 24.66% [3] - The sale of medical technology assets was driven by significant revenue decline and continuous losses in the smart medical sector, allowing the company to focus on its core commercial intelligence business [3][4] Group 4: Strategic Partnerships - The strategic cooperation with Cangnan government aims to enhance long-term collaboration in the smart business sector, leveraging shared resources for mutual growth [3] Group 5: Recent Financial Transactions - The sale of medical technology assets generated 562 million yuan, with 304 million yuan recorded as other business income and 11.21 million yuan as asset disposal gains in Q1 2025 [4]

Group 1: 2024 Overall Business Performance - The company achieved a total outpatient and emergency service volume of 2.5727 million, a year-on-year increase of 7.70% [1] - The inpatient service volume reached 205,700, reflecting a year-on-year growth of 10.73% [1] - The total operating revenue for the year was 4.815 billion, with a year-on-year increase of 4.28% [2] - The net profit attributable to the parent company was -254 million, a reduction in loss by 31.01% [2] Group 2: Q1 2025 Business Performance - In Q1 2025, the company reported an operating revenue of 999.7 million, a decrease of 14.99% compared to the same period last year [3] - The net profit attributable to the parent company was -106 million, a decline of 1.37% year-on-year [3] - The net operating cash flow was 244 million, indicating stable cash flow management [3] Group 3: 2024 Operational Highlights - Xi'an High-tech Hospital generated operating revenue of 1.525 billion, a year-on-year increase of 2.68% [3] - Xi'an International Medical Center Hospital achieved operating revenue of 3.274 billion, with a year-on-year growth of 7.60% [3] - The outpatient and emergency service volume at the International Medical Center Hospital reached 1.4182 million, a year-on-year increase of 18.88% [4] - The inpatient service volume was 139,700, reflecting a year-on-year growth of 15.32% [4] Group 4: Proton Center Project and Digitalization - The proton therapy center project is progressing, with the core component, the cyclotron, installed by June 18, 2024, and expected to be operational by the end of 2025 [5][6] - The company has completed local deployment of medical intelligent models, integrating with core business systems to enhance operational efficiency [7] Group 5: Quality Improvement and Service Expansion - The hospital is advancing its three-tier evaluation work, focusing on system optimization and quality enhancement [8] - The company is expanding into high-end medical services, including aesthetic medicine, rehabilitation, and proton therapy, to meet diverse health needs [9] - The company is adapting to ongoing healthcare policy reforms by refining operations and adjusting business structures to maintain service quality [10]

Investment Rating - The investment rating for the company is "Buy" and is maintained [7]. Core Views - The company's domestic performance is under short-term pressure, but it is expected to enter a recovery phase in 2025. In 2024, the company is projected to achieve revenue of 36.726 billion yuan, with domestic revenue of 20.292 billion yuan, reflecting a year-on-year decline of 5.10%. This decline is primarily due to tight local fiscal funding, a significant reduction in the issuance of medical special bonds, and delays in regular bidding for medical equipment updates. However, data from the first quarter of 2025 indicates a continuous recovery in the industry, with local special bonds for hospital renovations and equipment procurement showing rapid growth [2][4][9]. Summary by Sections Financial Performance - In 2024, the company achieved an operating income of 36.726 billion yuan, a year-on-year increase of 5.14%, and a net profit attributable to the parent company of 11.668 billion yuan, up 0.74%. In the first quarter of 2025, the company reported an operating income of 8.237 billion yuan, a year-on-year decrease of 12.12%, and a net profit of 2.629 billion yuan, down 16.81% [4][9]. Domestic and International Market Analysis - The domestic market is expected to face short-term challenges, but signs of recovery are emerging for 2025. The overseas market, however, is showing robust growth, with 2024 overseas revenue reaching 16.434 billion yuan, a year-on-year increase of 21.28%. The overseas business now accounts for approximately 45% of total revenue, with the company maintaining a top-three market share in various product categories globally [9]. Business Segments and Competitive Advantage - The company operates in three main business areas, supported by the "Smart Ecosystem" strategy. In the life information and support sector, revenue in 2024 was 13.557 billion yuan, down 11.11%. The in-vitro diagnostics segment saw revenue of 13.765 billion yuan, up 10.82%, while the medical imaging segment generated 7.498 billion yuan, a 6.60% increase. The company is actively promoting its laboratory solutions and cloud services, achieving significant installations in hospitals [9]. Future Outlook - The company is expected to see net profits of 13.082 billion yuan, 15.072 billion yuan, and 17.551 billion yuan for 2025, 2026, and 2027, respectively. The current stock price corresponds to price-to-earnings ratios of 20, 18, and 15 for the years 2025 to 2027 [9].

Core Insights - Aidi Kang Holdings (艾迪康控股) has announced the full acquisition of Yuande Youqin and Yuande Weikang, marking a strategic expansion in the blood testing sector with a total consideration of 50 million RMB in cash and 4% of the company's common stock [1][4] - The acquisition aims to enhance Aidi Kang's capabilities in high-end specialty testing, particularly in the blood disease diagnosis field, leveraging the expertise of Yuande Youqin and Yuande Weikang [1][5] Group 1: Business Expansion and Market Position - Aidi Kang is focusing on the specialty testing (特检) sector, which has become a core growth engine, with a projected revenue growth of over 18% year-on-year in 2024, particularly in tumor detection, which has seen a 47% increase [2][3] - The global blood testing market is expected to grow from approximately $90.6 billion in 2024 to $126.1 billion by 2029, with a compound annual growth rate (CAGR) of 6.88%, and the Chinese market is projected to reach 100 billion RMB by 2025 [3][4] Group 2: Strategic Acquisition Details - Yuande Youqin is recognized as a leading enterprise in blood disease diagnostics, providing over 200,000 testing services annually and covering more than 400 tertiary hospitals [5][6] - The acquisition will significantly enhance Aidi Kang's product line in blood testing, providing a comprehensive solution that includes both routine and high-end specialty tests, thereby improving clinical service capabilities [8][9] Group 3: Future Growth and Innovation - The partnership is expected to create a synergistic effect, enhancing Aidi Kang's market presence and driving the development of a "testing-reagents-clinical" integrated ecosystem [9] - The collaboration will leverage Yuande Youqin's extensive sample resource library and Aidi Kang's AI diagnostic technology to establish a closed-loop innovation system, promoting standardization and intelligence in the industry [8][9]

本报记者 陈 曦 日前，天津医科大学肿瘤医院研发的全国首个肿瘤重症全程数字化管理专科系统（以下简称"数字化系 统"）正式上线。依托该系统打造的智慧肿瘤重症诊疗场景、智慧医疗管理场景和智慧医学科研场景正 在改变肿瘤重症医学的临床治疗方式、质控管理方式和科研方式。 医生的"得力帮手" 来源：科技日报 肿瘤重症全程数字化管理专科系统在天津医科大学肿瘤医院投入使用。 【应用选萃】 精明的"数据管家" "在传统肿瘤重症诊疗场景中，重症监护室里的医生和护士就像数据搬运工，每日都面临着繁重的手工 记录工作。"天津医科大学肿瘤医院重症监护科主任王东浩回忆道，"人工获取数据不仅耗费大量时间和 精力，还容易出现遗漏与失误，难以为医疗决策提供可靠参考，给肿瘤治疗带来了诸多不确定性。" 如今，在智慧肿瘤重症诊疗场景下，数字化系统成了医生的"第三只眼"。 天津医科大学肿瘤医院重症监护科主任王东浩与团队分析系统数据。受访者供图 数字化系统实现了全域数据整合，可自动抓取床旁监护仪、呼吸机等设备数据，以及患者生命体征、病 情变化数据，并同步整合医院信息系统、实验室信息系统、医学影像存档与通信系统中的检验结果和影 像报告。一旦监测到异常数值， ...

Core Viewpoint - The Hong Kong stock market's positive performance reflects a global capital reallocation towards Asia-Pacific assets, particularly in the higher vocational education sector, which benefits from both consumer demand and policy incentives [1] Group 1: Financial Performance - In the first half of the 2025 fiscal year, the company achieved revenue of approximately 1.247 billion RMB, a year-on-year increase of 7.5%, driven by growth in student numbers and tuition fee increases [2] - The company’s student enrollment exceeded 100,000, marking a 4.4% increase compared to the previous year, with revenue growth from 554 million RMB in the first half of 2021 to 1.247 billion RMB in the first half of 2025, representing a cumulative increase of 125.27% [2] - The company maintains a healthy financial structure with a debt-to-asset ratio of only 44.44% and cash and cash equivalents amounting to 2.071 billion RMB [4] Group 2: Shareholder Returns - The board proposed an interim dividend of 0.066 HKD per share, with a payout ratio of 30%, marking the twelfth dividend distribution since the company went public [4] - Over the past three years, the total cash dividends exceeded 570 million RMB, demonstrating a commitment to returning value to shareholders [4][6] Group 3: Market Outlook - The company is optimistic about the development opportunities in the Guangdong-Hong Kong-Macao Greater Bay Area over the next 15 years, anticipating a significant demand for high-quality applied talent [6][10] - The Guangdong Provincial Education Department projects a 50% increase in student enrollment by 2035, with the company’s nine institutions forming a strategic network to meet diverse educational needs [9] Group 4: Strategic Initiatives - The company is actively enhancing its educational infrastructure and resources, including the acquisition of new educational land and the optimization of campus facilities [11] - It is focusing on integrating cutting-edge fields such as AI, new energy vehicles, and smart healthcare into its curriculum, collaborating with industry leaders to create a comprehensive talent training system [12][13] - The company aims to upgrade traditional disciplines to align with market demands, ensuring that its educational offerings remain relevant and competitive [13][14]

Core Viewpoint - Tianzhihang, a leading domestic surgical robot company, reported a narrowing loss in 2024 and a significant revenue growth of 102.40% in Q1 2025, indicating a recovery in the surgical robot market driven by increasing surgical volumes and optimized revenue structure [1][2][3]. Financial Performance - In 2024, Tianzhihang achieved operating revenue of 179 million yuan, with a net profit loss of 121 million yuan, a 22.54% improvement from a loss of 156 million yuan in 2023 [2]. - The company reported a revenue of 58.58 million yuan in Q1 2025, up from 28.94 million yuan in the same period of 2024, marking a year-on-year growth of over 102.40% [2]. Surgical Application Growth - The Tianji orthopedic surgical robot completed over 39,000 surgeries in 2024, a 62.5% increase from over 24,000 surgeries in 2023 [3]. - By the end of Q1 2025, the cumulative surgical volume exceeded 110,000 cases, reflecting a steady market demand [3]. Revenue Structure Optimization - Revenue from supporting equipment and consumables reached 54.86 million yuan in 2024, a year-on-year increase of 28.52%, while technical service revenue was 42.96 million yuan, up 104.26% [3]. - The proportion of these two revenue streams increased from approximately 30% in 2023 to 54.7% in 2024, indicating a shift towards more stable and recurring income sources [3]. Industry Landscape - The surgical robot industry is recognized as a key sector in smart healthcare, with a projected global market size of 63.12 billion USD by 2030 and a potential market size of 70.85 billion yuan in China, with a compound annual growth rate exceeding 30% [4]. - As of the end of 2024, 64 companies had 115 surgical robot products approved in China, with orthopedic surgical robots accounting for 47% of the total, indicating intense competition [4]. Product Development and Innovation - Tianzhihang has established a product development framework of "pre-research generation, conversion generation, and上市 generation," enhancing its continuous innovation capability [6]. - The company has expanded its orthopedic surgical robot product line to cover major orthopedic procedures, including total hip and knee replacements, reflecting progress in product platform development [6]. Market Expansion and Strategy - Tianzhihang has maintained its leading market share in the domestic orthopedic surgical robot market and has received CE certification for its orthopedic navigation systems, facilitating overseas market expansion [7]. - The company is implementing differentiated pricing strategies to cater to various levels of medical institutions, enhancing its adaptability in the market [7].

Core Viewpoint - Omron has established itself as a leader in health care devices, particularly in blood pressure monitors, and is expanding its innovative technologies to address cardiovascular risks, particularly atrial fibrillation [1][6][8]. Group 1: Company Overview - Omron established its first factory in China in 1993, making the Dalian facility the largest global production base for Omron's health care division [1]. - The company operates in four major business areas: health care, industrial automation, electronic components, and social solutions [2]. Group 2: Innovative Technology - The "Intellisense Afib" technology allows blood pressure monitors to simultaneously detect the risk of atrial fibrillation during blood pressure measurement [8]. - This technology is based on 50 years of pulse wave data and integrates AI to enhance the accuracy of atrial fibrillation detection [8]. Group 3: Market Position and Strategy - China accounts for 33% of Omron's global health care sales, highlighting its significance as a key market [6]. - The aging population and the rise of health-conscious younger generations present substantial growth opportunities for Omron's products [6]. Group 4: Product Development - The new generation blood pressure monitor, HCG-7800T, improves accuracy and ease of use, allowing for simultaneous blood pressure and atrial fibrillation detection [9]. - Omron has sold over 350 million home blood pressure monitors globally as of April 2023, indicating strong market penetration [11]. Group 5: Future Vision - Omron aims to achieve three zeros in its health care business: zero occurrences of cardiovascular events, zero deterioration of respiratory diseases, and zero limitations in daily life due to chronic pain [14].